EVER Pharma is a sponsor of the World Stroke Organization (WSO) and its goals to improve stroke care worldwide and supports educational projects and congresses organized by this excellent organization.
The WSO was founded in 2006 at the first World Stroke Congress in Cape Town, South Africa, on October 29th and since then World Stroke Day activities happen globally in late October including the World Stroke Congress (WSC) every 2 years.
Between October 25th-27th 2017, World Stroke Day was organized in Moscow jointly by the Russian Stroke Organization, the WSO Executive Committee and the Russian MoH strongly endorsed the meeting with an excellent attendance of over 2.600 delegates and faculty.
EVER Pharma was one of the major partners and organized 3 important events – two satellite symposia and the Editorial Board Meeting of the International Journal of Stroke (IJS) – Russian Language Edition.
Satellite Symposium 1 – Subacute Stroke Care and Neurorecovery
The first speaker was Prof Michael Brainin, President-Elect of the WSO and an expert of post-stroke cognition who gave a highly interesting talk about the latest pre-clinical research with Cerebrolysin® and how these data can be translated into clinical evidence, here especially focusing on the work done in Prof Michael Chopp’s laboratory in Henry Ford Hospital, Detroit, USA. In his review of the clinical data Prof Brainin discussed the existing evidence from Vascular Dementia studies which were also positively reviewed by the Cochrane Group. He also mentioned the E-Compass-Trial from Korea where for the first time fMRI imaging data demonstrate that Cerebrolysin® has a positive effect on plasticity and consequently on clinical outcome. He encouraged EVER Pharma in his talk to continue this promising work on the clinical development of Cerebrolysin®, especially in all VCI (Vascular Cognitive Impairment) related research areas.
He was followed by Prof Alla Guekht who authored and co-authored two major new publications with Cerebrolysin®, the CARS-Study and the CARS-Meta-Analysis. Both studies researched the effects of Cerebrolysin® in combination with structured rehabilitation versus rehabilitation alone. The results in both studies demonstrated that the double intervention of Cerebrolysin® plus rehabilitation is significantly superior while the safety of the pharmacological intervention is excellent, mortality in the Cerebrolysin® group was reduced as well.
Satellite Symposium 2 – Acute Stroke Care with Cerebrolysin®
Dr. Milan Vosko from Kepler University Hospital in Linz, Austria, presented an excellent overview about the clinical development of Cerebrolysin®, demonstrating that the evidence from smaller and larger trials has reached excellent levels especially in the last 5-7 years and that patients coming to his hospital are regularly treated with Cerebrolysin® for 10 days with a 30ml daily dosage.
Prof Dina Khasanova followed his talk with a very specific discussion about thrombolysis treatment with tPA in Russia in general, thrombolysis treatment protocols and how she uses Cerebrolysin® in combination with tPA. She also presented her own research data showing that Cerebrolysin® not only enhances the efficacy of tPA by reducing the NIHSS-Score in a continuous way (avoiding the so called humpback-effect when patients temporarily get worse again) but also reduces the cases of hemorrhagic transformation.